AVIR
|Atea Pharmaceuticals Inc
NASDAQ
USD 3.23
+0.01|+0.47%
Current Price
USD 3.23
Change
+USD 0.01 (0.47%)
P/E Ratio
Dividend Yield
Market Cap
252.46M
Volume
213,459
Open
USD 3.23
Previous Close
USD 3.22
52-Week High
USD 4.14
52-Week Low
USD 2.46
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Jean-Pierre Sommadossi Ph.D.
Employees:56
Headquarters:Boston, USA
Website:ateapharma.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions